Clinical Education InitiativeMenu
Home > Courses > The Impact of Antiretroviral Drugs on HBV Infection

The Impact of Antiretroviral Drugs on HBV Infection

The Impact of Antiretroviral Drugs on HBV Infection
Sorry, this learning module is not available for mobile devices.
Original Presentation: 2/9/2016
Web Posting: 6/6/2016
CE Expiration: 02/08/2019
  • Oluwaseun O Falade-Nwulia, MBBS, MPH
    Assistant Professor of Medicine
    Johns Hopkins University School of Medicine
Learning Objectives
At the completion of this educational session, participants will:
  1. Understand the epidemiology of HBV infection.
  2. Know the impact of HIV infection on HBV-related liver outcomes.
  3. Be aware of the impact of antiretroviral drugs on HBV.
  4. Have a better understanding of HBV in MSM with, and at risk for, HIV-infection.
Presenter Bio
Oluwaseun Falade-Nwulia, MBBS, MPH
Oluwaseun Falade-Nwulia, MBBS, MPH, is an assistant professor of medicine in the division of infectious diseases at the Johns Hopkins University School of Medicine. Dr. Falade-Nwulia earned her MBBS from the University of Ibadan Medical School College of Medicine. She completed her residency at Johns Hopkins Bayview Medical Center. She performed fellowships in infectious diseases at Johns Hopkins and a fellowship in critical care medicine at the National Institutes of Health.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on February 9, 2016 and will terminate February 8, 2019.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Falade-Nwulia (Presenter) had no relevant financial relationships to disclose. Dr. Falade-Nwulia submitted her slides in advance for adequate peer review, and will support her presentation and clinical recommendations with the best available evidence from the medical literature.

 Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.


  • This online video and post-activity evaluation are one hour in length.
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules